# Overdose Risk Management and Compensation in the Era of Naloxone

> **NIH NIH R01** · NEW YORK UNIVERSITY · 2022 · $68,742

## Abstract

Abstract
Opioid withdrawal is a regular occurrence among people who use illegal opioids involving acute physical and
psychological pain with potentially serious health consequences, including overdose. At the same time,
withdrawal is increasingly seen as an important juncture during which people who use illicit opioids may be
more receptive to treatment initiation, particularly medication for the treatment of opioid use disorder (MOUD),
which typically provides remediation from withdrawal. Yet, several studies have also indicated that at least
some people receiving MOUD treatment still regularly experience withdrawal. The reasons for this have not yet
been explored systematically. Nor is there a general empirical understanding of how these withdrawal
experiences in the context of MOUD may represent a barrier to treatment or treatment adherence, or how they
may differ between populations not engaged in treatment and those engaged in methadone and
buprenorphine maintenance. This mixed-method supplementary study will combine qualitative insights from
participants who experience regular and/or severe withdrawal in a longitudinal interview schedule with
quantitative survey analysis of the parent grant’s cohort study to examine a number of hypotheses related to
the associations between withdrawal, treatment, and risk of overdose. It aims to provide an empirical
understanding of how withdrawal impacts people who use illegal opioids’ treatment choices over time as well
as how withdrawal experiences in the context of MOUD may represent a barrier to treatment or treatment
adherence. Evaluating the withdrawal experiences of people in different treatment modalities, as well as those
not currently in MOUD, and assessing their impact on treatment decisions is essential to efforts to strengthen
and refine existing MOUD treatment protocols and to design tailored interventions to engage opioid users that
account for their experiences with opioid withdrawal. Moreover, since MOUD is recognized as among the most
effective strategies for reducing rates of overdose and transmission of blood-borne viruses like HIV and HCV,
improving uptake and retention in MOUD programs can significantly improve the healthcare outcomes of
people with opioid use disorder.

## Key facts

- **NIH application ID:** 10489510
- **Project number:** 3R01DA046653-04S1
- **Recipient organization:** NEW YORK UNIVERSITY
- **Principal Investigator:** Alexander S Bennett
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $68,742
- **Award type:** 3
- **Project period:** 2022-02-01 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10489510

## Citation

> US National Institutes of Health, RePORTER application 10489510, Overdose Risk Management and Compensation in the Era of Naloxone (3R01DA046653-04S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10489510. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*